Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, according to a secondary analysis of the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial from the same international author team being presented at this year’s European Congress on Obesity (ECO) in Malaga, Spain.